LYSOGENE
LYS | PA
Overview
Corporate Details
- ISIN(s):
- FR0013233475
- LEI:
- 969500T64RILK1RD0852
- Country:
- France
- Address:
- 18 RUE JACQUES DULUD, 92200 NEUILLY-SUR-SEINE
- Website:
- https://www.lysogene.com/
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
Lysogene’s determination to succeed is rooted in our deep understanding of the impact central nervous system (CNS) diseases have on patients and families, and springs from our founder whose own child was affected by a neurodegenerative disease. Our mission is to discover and develop innovative therapies to transform the lives of people with rare central nervous system disorders. Lysogene is a biopharmaceutical gene therapy company with lead programs in neurodegenerative lysosomal storage disorders that affect children.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
Chat, Summarize & Extract with AI!
You have of free filing views remaining.
Upgrade for unlimited access.
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2023-05-26 17:32 |
Delisting Announcement
Informations privilégiées / Autres communiqués
|
French | 84.9 KB | |
| 2023-05-26 17:32 |
Delisting Announcement
Inside Information / Other news releases
|
English | 83.2 KB | |
| 2023-05-26 10:00 |
Delisting Announcement
Informations privilégiées / Autres communiqués
|
French | 85.6 KB | |
| 2023-05-26 10:00 |
Legal Proceedings Report
Inside Information / Other news releases
|
English | 83.5 KB | |
| 2023-05-15 18:00 |
Legal Proceedings Report
Inside Information / Other news releases
|
English | 83.5 KB | |
| 2023-05-15 18:00 |
Legal Proceedings Report
Informations privilégiées / Autres communiqués
|
French | 85.6 KB | |
| 2023-04-29 18:00 |
Report Publication Announcement
Inside Information / News release on accounts, results
|
English | 82.9 KB | |
| 2023-04-29 18:00 |
Delisting Announcement
Informations privilégiées / Communiqué sur comptes, résultats
|
French | 85.1 KB | |
| 2023-04-14 18:00 |
M&A Activity
Inside Information / Other news releases
|
English | 83.2 KB | |
| 2023-04-14 18:00 |
Legal Proceedings Report
Informations privilégiées / Autres communiqués
|
French | 85.4 KB | |
| 2023-03-24 20:00 |
Legal Proceedings Report
Informations privilégiées / Autres communiqués
|
French | 95.8 KB | |
| 2023-03-24 20:00 |
Regulatory News Service
Inside Information / Other news releases
|
English | 93.5 KB | |
| 2023-02-16 18:00 |
Delisting Announcement
Inside Information / Other news releases
|
English | 107.8 KB | |
| 2023-02-16 18:00 |
Legal Proceedings Report
Informations privilégiées / Autres communiqués
|
French | 110.2 KB | |
| 2023-02-03 18:00 |
Board/Management Information
Informations privilégiées / Autres communiqués
|
French | 91.3 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
1NKEMIA | Spain | IKM | |
|
2cureX AB | Sweden | 2CUREX | |
|
4SC AG | Germany | VSC | |
|
Abera Bioscience AB | Sweden | ABERA | |
|
ABIONYX Pharma | France | ABNX | |
|
Abliva | Sweden | ABLI | |
|
AB Science | France | AB | |
|
Acticor Biotech | France | ALACT | |
|
Active Biotech | Sweden | ACTI | |
|
AcuCort AB | Sweden | ACUC |